Childhood Growth, Biological Aging and Midlife Cardio-Metabolic Outcomes
Childhood Growth, Biological Aging and Midlife Cardio-Metabolic Outcomes
批准号:
9750243
负责人:
WEI CHEN
金额:
$7.57万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-08-01 至 2020-04-30
关键词:
AdultAgeAgingAreaAtherosclerosisBackBiological AgingBiological MarkersBirthBirth CertificatesBirth WeightBody mass indexCardiovascular systemChildChildhoodChronologyComplexCoronary ArteriosclerosisDNA MethylationDataData AnalysesData SetDevelopmentDiseaseDisease OutcomeElderlyEnvironmental Risk FactorEpigenetic ProcessEthnic OriginEtiologyFetal GrowthGenderGene ExpressionGeneticGrantGrowthGrowth and Development functionHeartHeightHumanHypertensionIndividualInterventionJointsLeft Ventricular MassLengthLifeLongitudinal cohortMeasuresMediatingMediationMediator of activation proteinMetabolic DiseasesModelingModificationNatureNewborn InfantNon-Insulin-Dependent Diabetes MellitusOutcomePathway interactionsPatternPlant RootsPlayPopulationPrevention programPrevention strategyProcessProcess MeasurePublic HealthRaceResearchResearch Project GrantsRiskRisk FactorsRoleServicesSkinSystemTimeVariantage relatedagedarterial stiffnesscardiometabolic riskcardiometabolismcarotid intima-media thicknesscohortcourse sequencecritical periodexperiencegenetic variantgenome-widehealthy aginghigh riskhuman population studyinsightmiddle agemortalitynovel therapeutic interventionprenatal experienceresponsesecondary analysissuccesstelomeretime usetrend
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Middle age is a critical period for cardio-metabolic diseases, including coronary artery disease,
hypertension and type 2 diabetes. The importance of impact of childhood adverse growth
experience on adult cardio-metabolic diseases has long been recognized. Telomere length and
DNA methylation (DNAm) age are highly correlated with chronological age and considered as
biomarkers of human aging. Recent studies have clarified that changes in telomere length and
DNAm predict cardio-metabolic disease, atherosclerosis and mortality. Despite extensive studies
on the early origins of cardio-metabolic disease and biological aging, the combined effect of
prenatal experience, early life developmental patterns and cardio-metabolic aging process is not
well understood and remains an important research area. This secondary data analysis proposal is
directed to the following Specific Aims: 1) To examine the impact of early life growth trajectory
patterns on telomere age, DNAm age and cardio-metabolic disease in middle-aged black and
white adults; 2) To investigate the temporal relationship of BMI-telomere and BMI-DNAm and the
effect of their temporal sequence patterns on adult cardio-metabolic disease; 3) To determine the
mediation effect of telomere and DNAm aging biomarkers on the association of early life growth
and risk burden with adult cardio-metabolic risk; 4) To examine whether race, gender and birth
weight modify the association and mediation effect parameters. The cardio-metabolic outcomes
include hypertension, type 2 diabetes, coronary artery disease and subclinical cardiovascular
measures. Telomere length and DNAm age will be used as mediators. The specific aims will be
achieved by leveraging the existing longitudinal cohort of the Bogalusa Heart Study followed
from childhood since 1973. We propose to analyze two cohorts: a longitudinal cohort of 3,627
adults (2,285 whites and 1,342 blacks), aged 28-61 years, who have height, body mass index
(BMI), skin folds measured 3-9 times in childhood and 2-6 times in adulthood, and a sub-cohort of
1,168 adults (747 whites and 421 blacks) who also have telomere data and genome-wide 450K
DNAm profiles measured at two time-points 5-12 years apart in adulthood. Cross-lagged models
for temporal relationship analysis, mediation analysis models, regression models and interaction
analysis models will be performed. Findings on the impact of early life growth on cardio-metabolic
disease in relation to biological aging markers will facilitate identification of high risk individuals and
selection of novel therapeutic and intervention strategies in early life.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Targeting Grainyhead-Like 2 Suppresses Entry Factors of SARS-CoV-2 in Epithelial Cells of Oral Mucosa.
-
批准号:10453095
-
项目类别:
-
资助金额:$23.4万
-
财政年份:2022
-
负责人:WEI CHEN
-
依托单位:
Targeting Grainyhead-Like 2 Suppresses Entry Factors of SARS-CoV-2 in Epithelial Cells of Oral Mucosa.
-
批准号:10598134
-
项目类别:
-
资助金额:$19.5万
-
财政年份:2022
-
负责人:WEI CHEN
-
依托单位:
Protection of donor kidneys with synchronization modulation electric field (SMEF)
-
批准号:10705847
-
项目类别:
-
资助金额:$80.42万
-
财政年份:2021
-
负责人:WEI CHEN
-
依托单位:
Protection of donor kidneys with synchronization modulation electric field (SMEF)
-
批准号:10603207
-
项目类别:
-
资助金额:$80.33万
-
财政年份:2021
-
负责人:WEI CHEN
-
依托单位:
Protection of donor kidneys with synchronization modulation electric field (SMEF)
-
批准号:10384061
-
项目类别:
-
资助金额:$25.13万
-
财政年份:2021
-
负责人:WEI CHEN
-
依托单位:
Epigenetic regulation of radiation damage in oral mucosa
-
批准号:9005855
-
项目类别:
-
资助金额:$11.55万
-
财政年份:2015
-
负责人:WEI CHEN
-
依托单位:
Epigenetic regulation of radiation damage in oral mucosa
-
批准号:8824424
-
项目类别:
-
资助金额:$11.55万
-
财政年份:2015
-
负责人:WEI CHEN
-
依托单位:
Inhibition of Wnt/B-Catenin Signaling in Colorectal Cancer Therapy
-
批准号:8737810
-
项目类别:
-
资助金额:$31.6万
-
财政年份:2013
-
负责人:WEI CHEN
-
依托单位:
Inhibition of Wnt/B-Catenin Signaling in Colorectal Cancer Therapy
-
批准号:8891386
-
项目类别:
-
资助金额:$32.58万
-
财政年份:2013
-
负责人:WEI CHEN
-
依托单位:
Inhibition of Wnt/B-Catenin Signaling in Colorectal Cancer Therapy
-
批准号:9105816
-
项目类别:
-
资助金额:$32.58万
-
财政年份:2013
-
负责人:WEI CHEN
-
依托单位:
Inhibition of Wnt/B-Catenin Signaling in Colorectal Cancer Therapy
-
批准号:9321593
-
项目类别:
-
资助金额:$32.58万
-
财政年份:2013
-
负责人:WEI CHEN
-
依托单位:
Inhibition of Wnt/B-Catenin Signaling in Colorectal Cancer Therapy
-
批准号:8578066
-
项目类别:
-
资助金额:$32.58万
-
财政年份:2013
-
负责人:WEI CHEN
-
依托单位:
Evolution of Cardiovascular Risk with Normal Aging
-
批准号:8858472
-
项目类别:
-
资助金额:$67.25万
-
财政年份:2012
-
负责人:WEI CHEN
-
依托单位:
Childhood Secondhand Smoke and Longitudinal Cardiovascular Risk Profile
-
批准号:8545849
-
项目类别:
-
资助金额:$60.9万
-
财政年份:2012
-
负责人:WEI CHEN
-
依托单位:
Childhood Secondhand Smoke and Longitudinal Cardiovascular Risk Profile
-
批准号:8695396
-
项目类别:
-
资助金额:$59.77万
-
财政年份:2012
-
负责人:WEI CHEN
-
依托单位:
Childhood Secondhand Smoke and Longitudinal Cardiovascular Risk Profile
-
批准号:8341382
-
项目类别:
-
资助金额:$59.43万
-
财政年份:2012
-
负责人:WEI CHEN
-
依托单位:
NONINVASIVE STUDY OF CEREBRAL ATP METABOLISM, BIOENERGETICS AND BRAIN FUNCTION
-
批准号:8362840
-
项目类别:
-
资助金额:$3.03万
-
财政年份:2011
-
负责人:WEI CHEN
-
依托单位:
STUDY OF BRAIN OXIDATIVE METABOLISM BY 17-0 IMAGING
-
批准号:8362838
-
项目类别:
-
资助金额:$3.03万
-
财政年份:2011
-
负责人:WEI CHEN
-
依托单位:
Birth Weight, Postnatal Growth, Blood Pressure and Subclinical Cardiovascular Dis
-
批准号:8142177
-
项目类别:
-
资助金额:$7.15万
-
财政年份:2010
-
负责人:WEI CHEN
-
依托单位:
Genetic Modulation on the Relationship of Low Birth Weight to Metabolic Syndrome
-
批准号:8063469
-
项目类别:
-
资助金额:$7.15万
-
财政年份:2010
-
负责人:WEI CHEN
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: